Guillaume Fond1, Laurent Boyer2, Alexandru Gaman3, Hakim Laouamri3, Dodji Attiba3, Jean-Romain Richard4, Marine Delavest5, Josselin Houenou6, Philippe Le Corvoisier7, Dominique Charron8, Rajagopal Krishnamoorthy9, José Oliveira10, Ryad Tamouza7, Robert Yolken11, Faith Dickerson12, Marion Leboyer4, Nora Hamdani4. 1. INSERM U955, Équipe de Psychiatrie Translationnelle, Université Paris-Est Créteil, DHU Pe-psy, Pôle de psychiatrie des hôpitaux universitaire H Mondor, Créteil, France; Fondation FondaMental Fondation de coopération scientifique en santé mentale, France. Electronic address: guillaume.fond@gmail.com. 2. Fondation FondaMental Fondation de coopération scientifique en santé mentale, France; Pôle psychiatrie universitaire, CHU Sainte-Marguerite, F-13274 Marseille cedex 09, France. 3. Fondation FondaMental Fondation de coopération scientifique en santé mentale, France. 4. INSERM U955, Équipe de Psychiatrie Translationnelle, Université Paris-Est Créteil, DHU Pe-psy, Pôle de psychiatrie des hôpitaux universitaire H Mondor, Créteil, France; Fondation FondaMental Fondation de coopération scientifique en santé mentale, France. 5. Fondation FondaMental Fondation de coopération scientifique en santé mentale, France; AP-HP, Université Paris Diderot, Service de Psychiatrie, Hôpital Lariboisiere Fernand Widal, Paris, F-75010, France. 6. INSERM U955, Équipe de Psychiatrie Translationnelle, Université Paris-Est Créteil, DHU Pe-psy, Pôle de psychiatrie des hôpitaux universitaire H Mondor, Créteil, France; Fondation FondaMental Fondation de coopération scientifique en santé mentale, France; CEA Saclay, Neurospin, Gif-Sur-Yvette, France. 7. Jean Dausset Laboratory & INSERM, UMRS 940, Hôpital Saint Louis, Paris, France. 8. CIC 006 Henri Mondor INSERM & Plateforme de Ressources Biologiques, Université Paris Est Créteil, AP-HP, France. 9. INSERM, UMRS 665, INTS, Paris, France. 10. Fondation FondaMental Fondation de coopération scientifique en santé mentale, France; Jean Dausset Laboratory & INSERM, UMRS 940, Hôpital Saint Louis, Paris, France. 11. Stanley Laboratory of Developmental Neurovirology, Johns Hopkins University Medical Center, Baltimore, MD, USA; Stanley Research Program, Sheppard Pratt, Baltimore, MD, USA. 12. Stanley Research Program, Sheppard Pratt, Baltimore, MD, USA.
Abstract
OBJECTIVE: The association between Toxoplasma gondii seropositivity and respectively Bipolar Disorder (BD) and Schizophrenia/Schizoaffective disorder (SZ) is one of the most studied link between one pathogen and psychiatric disorders. The aim of the present study was thus to retrospectively determine if the administration of an antipsychotic and/or a mood stabilizer having known in vitro Anti-Toxoplasmic Activity (TATA+) was associated with a better clinical outcome in a population of 152 BD or 114 SZ patients and seropositive for T. gondii infection compared to patients receiving a treatment without anti-toxoplasmic activity (TATA-). METHODS: This multicenter study was conducted in an academic public hospital during a 3-years period between 2009 and 2011. All consecutive inpatients and outpatients with SZ or BD diagnosis with a stable treatment for more than 4 weeks were recruited. socio-demographic and clinical characteristics measured with validated scales as well as a serological status for toxoplasmic infection were included. Treatments were classified according to their in vitro antitoxoplasmic activity. A multivariate model was used to determine the clinical characteristics that were significantly different between patients receiving a treatment with no antitoxoplasmic activity compared to others. RESULTS: BD patients with positive serum antibodies against T. gondii presented more lifetime depressive episodes (p = 0.048) after adjustment for age, sex and sociodemographic characteristics when treated by drug having no anti-toxo activity, compared to patients having received drugs with anti-toxo activity. A significant difference was not found in BD toxonegative patients and in SZ toxopositive or toxonegative patients. CONCLUSIONS: It seems to be of importance to consider prescribing a drug with a clear anti-toxoplasmic activity (TATA+) for BD patients seropositive to T. gondii, in particular valproate that was found as the mood stabilizer with the highest antitoxoplasmic activity. Prospective randomized controlled trials are warranted to confirm this preliminary data.
OBJECTIVE: The association between Toxoplasma gondii seropositivity and respectively Bipolar Disorder (BD) and Schizophrenia/Schizoaffective disorder (SZ) is one of the most studied link between one pathogen and psychiatric disorders. The aim of the present study was thus to retrospectively determine if the administration of an antipsychotic and/or a mood stabilizer having known in vitro Anti-Toxoplasmic Activity (TATA+) was associated with a better clinical outcome in a population of 152 BD or 114 SZ patients and seropositive for T. gondii infection compared to patients receiving a treatment without anti-toxoplasmic activity (TATA-). METHODS: This multicenter study was conducted in an academic public hospital during a 3-years period between 2009 and 2011. All consecutive inpatients and outpatients with SZ or BD diagnosis with a stable treatment for more than 4 weeks were recruited. socio-demographic and clinical characteristics measured with validated scales as well as a serological status for toxoplasmic infection were included. Treatments were classified according to their in vitro antitoxoplasmic activity. A multivariate model was used to determine the clinical characteristics that were significantly different between patients receiving a treatment with no antitoxoplasmic activity compared to others. RESULTS: BD patients with positive serum antibodies against T. gondii presented more lifetime depressive episodes (p = 0.048) after adjustment for age, sex and sociodemographic characteristics when treated by drug having no anti-toxo activity, compared to patients having received drugs with anti-toxo activity. A significant difference was not found in BD toxonegative patients and in SZ toxopositive or toxonegative patients. CONCLUSIONS: It seems to be of importance to consider prescribing a drug with a clear anti-toxoplasmic activity (TATA+) for BD patients seropositive to T. gondii, in particular valproate that was found as the mood stabilizer with the highest antitoxoplasmic activity. Prospective randomized controlled trials are warranted to confirm this preliminary data.
Authors: Abhishek Wadhawan; Aline Dagdag; Allyson Duffy; Melanie L Daue; Kathy A Ryan; Lisa A Brenner; John W Stiller; Toni I Pollin; Maureen W Groer; Xuemei Huang; Christopher A Lowry; Braxton D Mitchell; Teodor T Postolache Journal: Pteridines Date: 2017-11-22 Impact factor: 0.581
Authors: Mark A Frye; Brandon J Coombes; Susan L McElroy; Lori Jones-Brando; David J Bond; Marin Veldic; Francisco Romo-Nava; William V Bobo; Balwinder Singh; Colin Colby; Michelle K Skime; Joanna M Biernacka; Robert Yolken Journal: JAMA Psychiatry Date: 2019-12-01 Impact factor: 21.596
Authors: G Fond; N Resseguier; F Schürhoff; O Godin; M Andrianarisoa; L Brunel; E Bulzacka; B Aouizerate; F Berna; D Capdevielle; I Chereau; T D'Amato; C Dubertret; J Dubreucq; C Faget; F Gabayet; C Lançon; P M Llorca; J Mallet; D Misdrahi; C Passerieux; R Rey; A Schandrin; M Urbach; P Vidailhet; L Boyer; M Leboyer Journal: Eur Arch Psychiatry Clin Neurosci Date: 2017-11-10 Impact factor: 5.270
Authors: Marion Leboyer; Michael Berk; Robert H Yolken; Ryad Tamouza; David Kupfer; Laurent Groc Journal: BMC Med Date: 2016-10-28 Impact factor: 8.775
Authors: Cosme Alvarado-Esquivel; Luis Francisco Sanchez-Anguiano; Jesus Hernandez-Tinoco; Luis Omar Berumen-Segovia; Yazmin Elizabeth Torres-Prieto; Sergio Estrada-Martinez; Alma Rosa Perez-Alamos; Maria Nalleli Ortiz-Jurado; Gabriel Molotla-de-Leon; Isabel Beristain Garcia; Elizabeth Rabago-Sanchez; Oliver Liesenfeld Journal: J Clin Med Res Date: 2016-05-29
Authors: Cosme Alvarado-Esquivel; Luis Francisco Sánchez-Anguiano; Jesús Hernández-Tinoco; Luis Omar Berumen-Segovia; Yazmin Elizabeth Torres-Prieto; Sergio Estrada-Martínez; Alma Rosa Pérez-Álamos; María Nalleli Ortiz-Jurado; Gabriel Molotla-de-León; Isabel Beristain-García; Elizabeth Rábago-Sánchez; Oliver Liesenfeld Journal: Eur J Microbiol Immunol (Bp) Date: 2016-04-25